<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753894</url>
  </required_header>
  <id_info>
    <org_study_id>1585-CL-0006</org_study_id>
    <nct_id>NCT02753894</nct_id>
  </id_info>
  <brief_title>Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia</brief_title>
  <official_title>Phase II Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to examine the clinical dose range of ASP1585 based on the
      efficacy, safety, and feasibility of treatment in chronic kidney disease patients on
      hemodialysis with hyperphosphatemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from the baseline of serum phosphorus level</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by AEs</measure>
    <time_frame>Up to 6 weeks after the study drug dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Hematology test</measure>
    <time_frame>Up to 6 weeks after the study drug dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Blood biochemistry tests</measure>
    <time_frame>Up to 6 weeks after the study drug dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Blood cogulability tests</measure>
    <time_frame>Up to 6 weeks after the study drug dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood concentration of Vitamin</measure>
    <time_frame>Up to 6 weeks after the study drug dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Vital signs</measure>
    <time_frame>Up to 6 weeks after the study drug dosing</time_frame>
    <description>Systolic blood pressure, diastolic blood pressure, heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by bowel movement</measure>
    <time_frame>Up to 6 weeks after the study drug dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by ECG</measure>
    <time_frame>Up to 6 weeks after the study drug dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course of serum phosphorus level</measure>
    <time_frame>Up to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of corrected serum calcium level</measure>
    <time_frame>Up to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of calcium-phosphorus product</measure>
    <time_frame>Up to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of intact parathyroid hormone</measure>
    <time_frame>Up to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who achieved the target serum phosphorus level (3.5 to 6.0 mg/dL)</measure>
    <time_frame>Up to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time achievement of the target serum phosphorus level (3.5 to 6.0 mg/dL)</measure>
    <time_frame>Up to Week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>4.5 g/day group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6.0 g/day group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5 g/day group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1585</intervention_name>
    <description>Oral</description>
    <arm_group_label>4.5 g/day group</arm_group_label>
    <arm_group_label>6.0 g/day group</arm_group_label>
    <arm_group_label>7.5 g/day group</arm_group_label>
    <other_name>Bixalomer</other_name>
    <other_name>Kiklin (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For preliminary enrollment

          -  Patients with stable chronic kidney disease who received hemodialysis 3 times a week
             for at least 12 weeks (84 days) prior to the day of preliminary enrollment

          -  Patients who did not have dialysis conditions altered (dialysate calcium
             concentration, dialyser, and dry weight) within 10 days prior to the day of
             preliminary enrollment

          -  Patients who did not have the following dosage or administration altered at least 28
             days prior to the day of preliminary enrollment: phosphate binders, or drugs/food with
             phosphate binding action (including newly started treatment)

          -  If receiving vitamin D or calcitonin agent, patients who did not have dosage and
             administration altered (including newly started treatment) for at least 28 days prior
             to the day of preliminary enrollment.

          -  Patients who did not use cinacalcet hydrochloride for at least 28 days prior to the
             day of preliminary enrollment

        For practical enrollment

          -  Patients whose pre-dialysis serum phosphorus level after the maximum dialysis interval
             at Week 1 of the washout period was ≥8.0 mg/dL and &lt;10.0 mg/dL or that at Week 2 was
             ≥6.0 mg/dL and &lt;10.0 mg/dL

          -  Patients who continued to receive hemodialysis 3 times a week after the day of
             preliminary enrollment

          -  Patients who did not have dialysis conditions altered (dialysate calcium concentration
             and dialyser) after the day of preliminary enrollment

          -  Patients who did not receive phosphate binders, or drugs/food with phosphate binding
             action during the washout period

          -  If receiving vitamin D or calcitonin agent (including start of new treatment) after
             the day of preliminary enrollment, patients who did not have dosage and administration
             altered for at least 28 days prior to the day of preliminary enrollment

          -  Patients who did not use cinacalcet hydrochloride after the day of preliminary
             enrollment

        Exclusion Criteria:

        For preliminary enrollment

          -  Patients with a history of gastrectomy or enterectomy (except for appendectomy) or
             with a complication of dysphagia, ileus, or hemorrhagic gastrointestinal lesions

          -  Patients with severe persistent constipation or diarrhoea

          -  Patients who underwent parathyroid intervention (parathyroidectomy [PTx], percutaneous
             ethanol injection therapy [PEIT], etc.) within 1 year prior to the day of preliminary
             enrollment

          -  Patients who are fasted or are on extreme dietary restrictions

          -  Patients with uncontrollable hypertension (all the last 3 measurement values of
             pre-dialysis systolic/diastolic blood pressure before the day of preliminary
             enrollment are ≥180 mmHg and ≥120 mmHg, respectively)

          -  Patients with severe heart disease (congestive heart failure [NYHA cardiac function
             classification Class III or severer], a history of extensive old myocardial
             infarction, etc.) or patients who were hospitalized for the treatment of
             cerebrovascular disease or heart disease within 12 weeks (84 days) prior to the day of
             preliminary enrollment

          -  Patients with a complication of serious hepatic disease (acute and active chronic
             hepatitis, hepatic cirrhosis, etc.)

          -  Patients with a history of serious drug hypersensitivity, such as anaphylactic shock

          -  Patients with a history or complication of malignant tumor (considered eligible if
             recurrence has not been observed for at least 5 years)

          -  Patients who are pregnant, nursing, suspected to be pregnant, or wish to become
             pregnant during the study period

          -  Patients who have previously received ASP1585

          -  Patients who participated in another clinical study or a post-marketing clinical study
             (including that of a medical device) within 12 weeks (84 days) prior to informed
             consent

        For practical enrollment

          -  Patients whose pre-dialysis serum phosphorus level after the maximum dialysis interval
             at Week 1 or 2 of the washout period was ≥10 mg/dL

          -  Patients who underwent gastrectomy or enterectomy, or had dysphagia, ileus, or
             hemorrhagic gastrointestinal lesions after the day of preliminary enrollment

          -  Patents who had severe persistent constipation or diarrhoea after the day of
             preliminary enrollment

          -  Patients who underwent parathyroid intervention (parathyroidectomy [PTx], percutaneous
             ethanol injection therapy [PEIT], etc.) after the day of preliminary enrollment

          -  Patients who were fasted or on extreme dietary restriction after the day of
             preliminary enrollment

          -  Patients with uncontrollable hypertension (more than two thirds of pre-dialysis
             systolic/diastolic blood pressure values were ≥180 mmHg and ≥120 mmHg, respectively,
             after the day of preliminary enrollment)

          -  Patients with severe heart disease (congestive heart failure [NYHA cardiac function
             classification Class III or severer], etc.) or patients who were hospitalized for the
             treatment of cerebrovascular disease or heart disease after the day of preliminary
             enrollment

          -  Patients with a complication of impaired liver function (baseline AST or ALT was 100
             IU/L or higher) or serious hepatic disease (acute and active chronic hepatitis, liver
             cirrhosis, etc.)

          -  Patients who experienced serious drug hypersensitivity such as anaphylactic shock
             after the day of preliminary enrollment

          -  Patients with a complication of malignant tumor

          -  Patients who were found to be pregnant after the day of preliminary enrollment

          -  Patients who participated in another clinical study or a post-marketing clinical study
             (including that of a medical device) after the day of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00011</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00009</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00010</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00006</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00007</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00008</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00002</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00003</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00004</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00005</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>June 17, 2016</last_update_submitted>
  <last_update_submitted_qc>June 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose-finding</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>ASP1585</keyword>
  <keyword>Chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

